CY1123075T1 - Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες - Google Patents

Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες

Info

Publication number
CY1123075T1
CY1123075T1 CY20201100575T CY201100575T CY1123075T1 CY 1123075 T1 CY1123075 T1 CY 1123075T1 CY 20201100575 T CY20201100575 T CY 20201100575T CY 201100575 T CY201100575 T CY 201100575T CY 1123075 T1 CY1123075 T1 CY 1123075T1
Authority
CY
Cyprus
Prior art keywords
corticosteroid
pi3k delta
dual pi3k
administration
compositions
Prior art date
Application number
CY20201100575T
Other languages
English (en)
Inventor
Swaroop KUMAR VENKATA SATYA VAKKALANKA
Srikant Viswanadha
Original Assignee
Rhizen Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S.A. filed Critical Rhizen Pharmaceuticals S.A.
Publication of CY1123075T1 publication Critical patent/CY1123075T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Η παρούσα αποκάλυψη αφορά μία μέθοδο αγωγής αυτοάνοσων, αναπνευστικών και/ή φλεγμονωδών νόσων ή καταστάσεων, π.χ., άσθματος, ΧΑΠ, ρευματοειδούς αρθρίτιδας και ιδιοπαθούς πνευμονικής ίνωσης (IPF). Η μέθοδος περιλαμβάνει χορήγηση ενός διπλού αναστολέα ΡΙ3Κ δέλτα και γάμα και ενός κορτικοστεροειδούς. Η παρούσα εφεύρεση αφορά επίσης φαρμακευτικές συνθέσεις που περιέχουν έναν διπλό ΡΙ3Κ δέλτα και γάμα αναστολέα και ένα κορτικοστεροειδές.
CY20201100575T 2014-09-03 2020-06-23 Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες CY1123075T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4287CH2014 2014-09-03
PCT/IB2015/056720 WO2016035032A1 (en) 2014-09-03 2015-09-03 Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid

Publications (1)

Publication Number Publication Date
CY1123075T1 true CY1123075T1 (el) 2021-10-29

Family

ID=54249540

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100575T CY1123075T1 (el) 2014-09-03 2020-06-23 Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες

Country Status (25)

Country Link
US (2) US10786504B2 (el)
EP (2) EP3188759B1 (el)
JP (3) JP6559775B2 (el)
KR (1) KR20170044203A (el)
CN (2) CN106714842B (el)
AU (2) AU2015310545B2 (el)
BR (1) BR112017004163A2 (el)
CA (1) CA2958988A1 (el)
CL (1) CL2017000512A1 (el)
CY (1) CY1123075T1 (el)
DK (1) DK3188759T3 (el)
EA (2) EA038527B1 (el)
ES (1) ES2802202T3 (el)
HR (1) HRP20200968T1 (el)
HU (1) HUE049480T2 (el)
IL (2) IL250918B (el)
LT (1) LT3188759T (el)
MX (2) MX2017002878A (el)
PH (1) PH12017500378A1 (el)
PL (1) PL3188759T3 (el)
PT (1) PT3188759T (el)
RS (1) RS60450B1 (el)
SG (2) SG11201701499YA (el)
SI (1) SI3188759T1 (el)
WO (1) WO2016035032A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116492351B (zh) * 2023-03-13 2024-03-12 香港大学深圳医院 氯替泼诺在制备治疗早发性卵巢功能不全及卵巢响应匮乏药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018774A (en) 1976-02-13 1977-04-19 E. R. Squibb & Sons, Inc. Steroidal [16α,17-d]isoxazolidines
SE8106165L (sv) 1981-10-19 1983-04-20 Atlas Copco Ab Forfarande for bergbultning och bergbult
GB0415747D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010002804A2 (en) 2008-07-01 2010-01-07 Wisconsin Alumni Research Foundation Method and compositions for inhibition of double stranded dna viruses
WO2010110747A1 (en) * 2009-03-24 2010-09-30 National University Of Singapore Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (copd)
WO2011029547A2 (en) 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
MY173795A (en) 2009-11-05 2020-02-24 Incozen Therapeutics Pvt Ltd Novel benzopyran kinase modulators
AU2011210640A1 (en) * 2010-01-28 2012-06-07 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
CN103391945B (zh) 2011-03-15 2016-11-09 奇斯药制品公司 异噁唑烷衍生物
MY168757A (en) * 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
SE540189C2 (en) 2012-05-22 2018-04-24 Epiroc Canada Inc Rock bolt and method of installing the rock bolt and a protecting sleeve for it
CN104870017B (zh) * 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
CN204282361U (zh) 2014-12-11 2015-04-22 湖南科技大学 一种带钢丝网的软土地基充气锚杆

Also Published As

Publication number Publication date
US10786504B2 (en) 2020-09-29
SG10202100596SA (en) 2021-02-25
AU2015310545B2 (en) 2020-10-22
IL250918B (en) 2021-02-28
HUE049480T2 (hu) 2020-09-28
EP3188759A1 (en) 2017-07-12
CL2017000512A1 (es) 2017-11-03
AU2015310545A1 (en) 2017-03-16
LT3188759T (lt) 2020-07-10
DK3188759T3 (da) 2020-06-29
JP2019172708A (ja) 2019-10-10
EA201790379A1 (ru) 2017-06-30
RS60450B1 (sr) 2020-07-31
AU2021200051A1 (en) 2021-02-18
EP3701950A1 (en) 2020-09-02
CA2958988A1 (en) 2016-03-10
SI3188759T1 (sl) 2020-08-31
SG11201701499YA (en) 2017-03-30
EP3188759B1 (en) 2020-04-01
MX2020011472A (es) 2020-12-07
NZ729419A (en) 2021-08-27
US20210030757A1 (en) 2021-02-04
EA202092492A1 (ru) 2021-07-30
HRP20200968T1 (hr) 2020-10-16
CN106714842B (zh) 2021-07-02
PH12017500378A1 (en) 2017-07-17
WO2016035032A1 (en) 2016-03-10
MX2017002878A (es) 2017-05-30
PL3188759T3 (pl) 2020-11-02
US20170281630A1 (en) 2017-10-05
KR20170044203A (ko) 2017-04-24
EA038527B1 (ru) 2021-09-10
JP2021191804A (ja) 2021-12-16
IL280686A (en) 2021-03-25
ES2802202T3 (es) 2021-01-15
PT3188759T (pt) 2020-07-02
BR112017004163A2 (pt) 2017-12-05
IL250918A0 (en) 2017-04-30
JP6559775B2 (ja) 2019-08-14
JP2017525739A (ja) 2017-09-07
CN113332439A (zh) 2021-09-03
CN106714842A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201590721A1 (ru) Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
SG10201913575VA (en) Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
HK1253537A1 (zh) 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
IN2014CH00840A (el)
CY1123075T1 (el) Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες
CR20200183A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний